Allogene Therapeutics (ALLO) Invested Capital (2017 - 2026)

Allogene Therapeutics' Invested Capital history runs 10 years deep, the most recent figure standing at $278.9 million for Q1 2026.

• In Q1 2026, Invested Capital fell 27.64% year-over-year to $278.9 million; the TTM figure through Mar 2026 stood at $278.9 million (down 27.64% YoY), while the FY2025 annual figure was $292.5 million, down 30.71% from the prior year.
• Invested Capital came in at $278.9 million for Q1 2026 at Allogene Therapeutics, down from $292.5 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $865.3 million in Q1 2022 to a low of $278.9 million in Q1 2026.
• A 5-year average of $521.6 million and a median of $512.2 million in 2023 frame the typical range for Invested Capital.
• On a YoY basis, Invested Capital climbed as much as 16.47% in 2025 and fell as far as 33.1% in 2025.
• Allogene Therapeutics' Invested Capital stood at $666.9 million in 2022, then decreased by 23.19% to $512.2 million in 2023, then decreased by 17.58% to $422.2 million in 2024, then sank by 30.71% to $292.5 million in 2025, then fell by 4.67% to $278.9 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $278.9 million, $292.5 million, and $315.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison